Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 708 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IT Injection Clear all
Recruiting Phase 2Phase 3 Interventional

Ketamine & Crisis Response Plan for Suicidal Ideation in the ED

NCT05696691
View directory record Official record
Conditions
Suicide
Interventions
Ketamine Hydrochloride, Crisis Response Plan
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 1 Interventional Results available

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

NCT03010176
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
Ulevostinag, Pembrolizumab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 23, 2026, 6:42 AM EDT
Terminated Phase 1 Interventional

CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

NCT05094206
View directory record Official record
Conditions
B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia
Interventions
0.75x10^6 cells/kg CAR20.19.22 cells, 1x10^6 cells/kg CAR20.19.22 cells, 2.5x10^6 cells/kg CAR20.19.22 cells, 5x10^6 cells/kg CAR20.19.22 cells, Dose expansion: The maximum tolerated dose of CAR20.19.22 cells
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 6:42 AM EDT
Terminated Phase 4 Interventional Results available

Vital Capacity in Ultrasound Guided Serratus Plane Block in ED Patients With Multiple Rib Fractures

NCT04530149
View directory record Official record
Conditions
Pain
Interventions
Acetaminophen, Bupivacain, Saline
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

NCT04133909
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mepolizumab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
88
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 72 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®

NCT00920647
View directory record Official record
Conditions
Hunter Syndrome
Interventions
Control, Idursulfase IT (1 mg), Idursulfase IT (10 mg), Idursulfase IT (30 mg)
Other · Drug
Lead sponsor
Shire
Industry
Eligibility
3 Years to 18 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 23, 2026, 6:42 AM EDT
Active, not recruiting Phase 2 Interventional

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

NCT05069038
View directory record Official record
Conditions
Breast Cancer
Interventions
Palbociclib 125mg
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

NCT03259425
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, HF10
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Oct 23, 2026, 6:42 AM EDT
Recruiting No phase listed Observational

The Effects of Stellate Ganglion Block Sleep in U.S. Active Duty Service Members and Veterans Receiving Prolonged Exposure Therapy for PTSD

NCT07667309
View directory record Official record
Conditions
Post Traumatic Stress Disorder PTSD
Interventions
Sleep Profiler Headband
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Killeen, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 1 Interventional

A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma

NCT01672450
View directory record Official record
Conditions
Melanoma
Interventions
Intratumoral Ipilimumab and Interleukin-2
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Not applicable Interventional Results available

Views on COVID-19 and Vaccination

NCT04706403
View directory record Official record
Conditions
Covid19
Interventions
Communication from a physician about the COVID-19 Vaccine
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 23, 2026, 6:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

NCT07061574
View directory record Official record
Conditions
Type 1 Diabetes, New Onset
Interventions
Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
9 Years to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Terminated Phase 3 Interventional Results available

Inositol to Reduce Retinopathy of Prematurity

NCT01954082
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
myo-Inositol 5% Injection, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
12 Hours to 72 Hours
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 23, 2026, 6:42 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults

NCT07888088
View directory record Official record
Conditions
Epstein Barr Virus (EBV) Infection
Interventions
MVA-BN-EBV, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 30 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

NCT03007979
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
Interventions
Palbociclib, Letrozole, Fulvestrant, Optional research biopsy, Goserelin, Research blood draw, Circulating tumor cell blood draw, Tumor biopsy (optional)
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
St Louis, Missouri • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

RHA® 4 With New Anesthetic - Nasolabial Folds

NCT04087395
View directory record Official record
Conditions
Aging, Pain
Interventions
RHA®4 with new anesthetic agent, RHA®4-Lidocaine
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Beverly Hills, California • Coral Gables, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 4 Interventional Results available

Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery

NCT05887375
View directory record Official record
Conditions
Spine Surgery, Reversal of Neuromuscular Blockade, Urinary Retention Postoperative
Interventions
Sugammadex, Neostigmine, Glycopyrrolate, Rocuronium
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 1 Interventional

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

NCT03349281
View directory record Official record
Conditions
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions
Pevonedistat, Vincristine, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Hydrocortisone
Drug
Lead sponsor
Julio Barredo, MD
Other
Eligibility
16 Years to 39 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 23, 2026, 6:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

NCT03942328
View directory record Official record
Conditions
Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Atezolizumab, Bevacizumab, External Beam Radiation Therapy, Pheresis, Pneumococcal 13-valent Conjugate Vaccine, Therapeutic Autologous Dendritic Cells, Durvalumab, Esophagogastroduodenoscopy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biopsy Procedure, Biospecimen Collection
Biological · Radiation · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)

NCT01839656
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
nusinersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
21 Days to 210 Days
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Stanford, California • Orlando, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD

NCT00320775
View directory record Official record
Conditions
Macular Degeneration
Interventions
VEGF Trap
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
8
States / cities
Tuscon, Arizona • Loma Linda, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone

NCT02617628
View directory record Official record
Conditions
Opiate Dependence
Interventions
extended release naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

NCT03273712
View directory record Official record
Conditions
Neuroendocrine Tumors, Meningioma, Neuroblastoma, Medulloblastoma
Interventions
90Y-DOTA tyr3-Octreotide, 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan, Amino Acids
Radiation · Diagnostic Test · Drug
Lead sponsor
University of Iowa
Other
Eligibility
6 Months to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 23, 2026, 6:42 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

NCT05503264
View directory record Official record
Conditions
NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
Interventions
Satralizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
11
States / cities
Birmingham, Alabama • Newport Beach, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 6:42 AM EDT